In tertiary obstetric units where caesarean delivery is managed alongside postpartum hemorrhage protocols, carbetocin acetate is processed into a single-dose aqueous injection at a nominal strength of 100 µg/mL expressed as carbetocin free peptide. The API is dissolved in water for injection after stoichiometric adjustment for its acetate salt form and the measured peptide content factor, typically 0.95–1.05 relative to the assayed anhydrous substance; the batch record requires an assay-driven input rather than a fixed gross-weight addition because peptide content varies between synthetic lots. Sodium chloride is added at approximately 9 mg/mL to approach physiological osmolality, and the solution is buffered with dilute acetic acid/acetate to an acidic pH typical of peptide acetate injection stability, commonly controlled between 3.5 and 4.5 unless the reference product dossier specifies a narrower range. The bulk solution is held at 2–8 °C under nitrogen blanketing to limit oxidative degradation, clarified through a 0.45 µm polyethersulfone prefilter, and sterilized by filtration through a validated 0.22 µm PVDF filter. Filling is executed on an isolator or open-RABS line under EU GMP Annex 1 Grade A conditions into Type I borosilicate glass vials with bromobutyl rubber stoppers and aluminum flip-off seals. The terminal presentation is a clear, colourless single-dose vial or ampoule containing 1.0 mL of solution for intravenous or intramuscular administration after 100% visual inspection and leak testing. The relevant quality framework includes Ph. Eur. general texts 5.1.1, 2.6.1, 2.6.14, 2.9.19, and 2.9.3, together with ICH Q3D elemental impurity risk assessment and FDA 21 CFR 211 current good manufacturing practice. On multi-lane filling lines, batch-to-batch variance is dominated by fill-weight drift caused by pump cavitation when static head space falls below 200 mm in the holding vessel; in-process check-weighing every 120 seconds with rejection of units outside the ±5% fill-volume tolerance reduces that variability. Filter integrity is tested by bubble point or water intrusion after filling, and the batch is rejected if the test fails. The solution must not be mixed with other medicinal products in the same syringe unless compatibility and peptide adsorption to plastic surfaces have been demonstrated; published data for carbetocin admixtures beyond the registered product configuration is limited.

What Distinguishes Heat-Stable Carbetocin Injection for Peripheral Obstetric Care?

Peripheral obstetric units that lack reliable cold-chain refrigeration require a heat-stable aqueous carbetocin presentation differentiated from oxytocin by storage and transport data generated under ICH Q1A Zone IVb conditions at 30 °C/75% RH and 40 °C/25% RH. The clinical target remains the same nominal peptide concentration of 100 µg/mL, but the release specification adds extended stability-indicating tests for deamidation, aggregation, and colour. API addition follows the same assay-based correction for peptide content and acetate counterion, with no added overage beyond the monograph assay range; stabilizer and buffer selection in the marketed formulation is proprietary, and the manufacturing route is aseptic filtration through a 0.22 µm filter rather than terminal sterilization. The downstream production process must control residual oxygen in the headspace to maintain the oxidation profile, typically by purging with nitrogen to a headspace oxygen level below 0.5% v/v and using aluminum overseals to limit gas permeation. The terminal product is a single-dose ampoule or vial for intramuscular or intravenous administration in primary care facilities, specifically for the prevention of postpartum hemorrhage and not for induction or augmentation of labour. Compliance is anchored to the WHO 2018 recommendations on uterotonics for PPH prevention, WHO/UNFPA/UNICEF product specifications where applicable, EU GMP Annex 1 for aseptic processing, and ICH Q1E for stability data extrapolation. The operational boundary is that removing cold-chain requirements does not remove temperature excursion limits; brief exposure to temperatures above 40 °C during freight must be supported by high-temperature excursion data, or the batch is rejected. This scenario differs from tertiary hospital manufacture not in the API concentration but in the freight qualification, stability protocol, packaging barrier requirements, and release specification for degradation products.

Veterinary Injectable Delivery in Porcine and Bovine Obstetrics

In veterinary medicine, carbetocin is authorized in certain jurisdictions for the management of uterine atony and retained fetal membranes in sows and cows, where the dosage expression is lower than the human obstetric concentration and the regulatory route is Directive 2001/82/EC or national veterinary medicines legislation. Marketed porcine formulations are typically presented at 35 µg/mL to 70 µg/mL carbetocin; API addition is based on the anhydrous, solvent-free peptide content and requires correction for the acetate salt, with the final concentration verified by high-performance liquid chromatography against a veterinary reference standard. The manufacturing process may include moist-heat terminal sterilization at 121 °C for 15 min where terminal sterilization is supported by stability data; otherwise, aseptic filtration through a 0.22 µm filter is used. Filling equipment for veterinary products often handles polypropylene or cyclic olefin copolymer bottles rather than Type I glass vials, so extractable/leachable studies under VICH GL18 must reflect the actual container material. The terminal product is an injectable solution for subcutaneous or intramuscular use in sows or cattle, typically packaged in 50 mL or 100 mL multidose vials requiring an approved antimicrobial preservative where pharmacopoeial multidose criteria apply. Quality testing includes sterility by Ph. Eur. 2.6.1, endotoxin by 2.6.14, preservative efficacy by 5.1.3, and veterinary stability data according to VICH GL3. The critical operational boundary is species-specific: administration to animals with mechanical obstruction of the birth canal or closed cervix is contraindicated because the oxytocic effect increases intrauterine pressure; this is a limitation carried directly from the pharmacological mechanism. Published data for some marketed veterinary formulations remain limited because veterinary registration dossiers are not always public; therefore, the exact excipient ratio must be confirmed against the reference product SmPC.

Because carbetocin is a cyclic octapeptide with a molecular weight of approximately 988 g/mol, oral solid-dose development is constrained by acid lability and brush-border peptidases, so no commercial oral carbetocin tablet or capsule is established. Preformulation screening uses enteric-coated tablets or capsules at carbetocin loadings of 0.1 mg to 1.0 mg per unit; published data for this specific configuration is limited, and the cited range should be treated as a development screening range rather than an approved dosage. Permeation enhancers such as sodium caprate or lauroyl carnitine may be incorporated at 10–50% w/w of the core matrix to modify tight junctions, but this high excipient load can compromise tablet tensile strength and requires roller compaction or dry granulation rather than aqueous wet granulation. The downstream process for prototype manufacture involves blending the peptide with a moisture-protective filler such as mannitol or anhydrous calcium hydrogen phosphate, roller compaction at a specific compaction force below 6 kN/cm to avoid heat and shear-induced aggregation, milling to a granule fraction between 125 µm and 710 µm, and compression or encapsulation with an enteric coating composed of methacrylic acid-ethyl acrylate copolymer. Dissolution testing is conducted according to Ph. Eur. 2.9.3 disintegration and 2.9.4 dissolution or USP 711, with a two-stage medium of 0.1 M hydrochloric acid followed by phosphate buffer pH 6.8; however, the absence of a pharmacopoeial monograph for oral carbetocin means that each prototype requires an internal specification. The terminal product type is an investigational enteric-coated tablet or HPMC capsule intended for dose-titration studies, and it is not a commercial finished medicine. The operational limitation is unambiguous: oral bioavailability is too low for therapeutic equivalence to the 100 µg/mL injection in published reports, and any downstream investment in oral dosage development must be supported by Phase I pharmacokinetic data before process scale-up.

If a Lyophilized Presentation Is Specified, What Manufacturing Parameters Govern Cake Stability?

When a development brief specifies a lyophilized carbetocin injection to extend shelf life beyond the aqueous solution profile, the formulation and freeze-drying cycle become the main sources of batch-to-batch variance. The pre-lyophilization liquid is compounded to a carbetocin concentration of 100 µg/mL or 500 µg/mL depending on the planned reconstitution volume, with a bulking agent such as mannitol or trehalose at 20–50 mg/mL to yield a mechanically stable cake and a buffer that does not crystallize selectively during freezing. The API addition ratio is calculated on an anhydrous and acetate-free basis, and the bulk solution is filtered through a 0.22 µm sterilizing-grade PVDF filter after the excipients are dissolved and pH is adjusted to the acidic target established for the reference aqueous injection; a typical aqueous acetate-buffered peptide solution falls between 3.5 and 4.5, with the registered range taken from stability data. The lyophilization cycle requires a controlled freezing ramp of 0.5–1.0 °C/min to −40 °C or lower, followed by annealing at −10 °C to −20 °C for crystallizable bulking agents, primary drying at a shelf temperature of −25 °C to −10 °C with chamber pressure between 100 mTorr and 200 mTorr, and secondary drying at 30 °C to 40 °C until residual moisture is below 1.0% w/w. In-process controls include comparative pressure measurement for primary drying end-point detection and thermocouple or manometric temperature measurement; batch rejection occurs if the cake collapses, melts back, or exceeds the residual moisture specification. The terminal product is a lyophilized cake in a Type I glass vial sealed under vacuum or nitrogen, reconstituted with water for injection to 1 mL before intramuscular or intravenous use. Compliance falls under Ph. Eur. 2.6.1 sterility, 2.6.14 endotoxins, 2.9.19 particulate matter, and ICH Q1A for storage stability; the lyophilized presentation also requires a reconstitution time specification. The operational limitation is that lyophilized carbetocin is not interchangeable with the ready-to-use aqueous product without a separate marketing authorization, and higher mannitol concentrations may require a post-reconstitution osmolality specification to avoid hypertonicity at the point of injection.

Granule and capsule intermediate preparation requires dry granulation when carbetocin peptide content is below 1.0% w/w

For granule and capsule intermediate manufacturing of experimental oral carbetocin, direct compression and aqueous wet granulation are generally unsuitable because the peptide is present at very low mass fractions and moisture exposure accelerates aggregation. Dry granulation by roller compaction is therefore used to produce granules at a carbetocin loading of 0.05–1.0% w/w, with the API first geometrically diluted with mannitol or anhydrous lactose in three stages to achieve a relative standard deviation of blend content below 5.0%. The addition ratio in the final capsule blend is set by the targeted dose of 0.25 mg, 0.5 mg, or 1.0 mg per unit, with crospovidone fixed at 2–5% w/w and magnesium stearate limited to 0.5–1.0% w/w to avoid reducing dissolution of the peptide. The downstream process uses a roller compactor with a roll surface speed below 15 rpm and a specific compaction force between 2 kN/cm and 6 kN/cm, followed by milling through a 0.8 mm screen and encapsulation into HPMC capsules on a low-speed capsule filler. Blend uniformity is verified by Ph. Eur. 2.9.40, capsule disintegration by 2.9.3, and dissolution by 2.9.4 or USP 711; because no oral carbetocin monograph exists, identity and purity are tested by a stability-indicating liquid chromatography method. The terminal product type is an HPMC capsule containing dry granulate for preclinical or Phase I dose-ranging studies; this is not a commercial finished oral dosage form. The operational limitation is that roller compaction may generate amorphous peptide domains at higher specific compaction forces, and the increase in apparent solubility does not translate to acceptable oral bioavailability unless a permeation enhancer is retained within the granule matrix. Relative humidity below 40% RH is maintained throughout blending, compaction, and encapsulation because low-dose peptide blends are prone to electrostatic adhesion to stainless steel surfaces; ionized air is used at the discharge chute to reduce that failure mode.